Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 304, Issue 11, 2013, Pages

  Rosenbaugh, Erin G ^a   Savalia, Krupa K ^a   Manickam, Devika S ^b   Zimmerman, Matthew C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b University of North Carolina at Chapel Hill   (United States)

Author keywords

Angiotensin; Antioxidants; Cardiovascular disease; Free radical scavengers; Oxidative stress; Therapy

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN II; ANTIOXIDANT; ASCORBIC ACID; CANDESARTAN; CATECHIN; MACROGOL; NARINGENIN; PORPHYRIN; QUERCETIN; RESVERATROL; SCAVENGER; TEMPOL; TROLOX C;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CEREBROVASCULAR ACCIDENT; DIABETIC NEPHROPATHY; DIET SUPPLEMENTATION; DRUG MECHANISM; DRUG MEGADOSE; GENE THERAPY; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; ISCHEMIC HEART DISEASE; MYOCARDIAL DISEASE; NANOMEDICINE; NANOTECHNOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION INJURY; REVIEW;

ANGIOTENSIN; ANTIOXIDANTS; CARDIOVASCULAR DISEASE; FREE RADICAL SCAVENGERS; OXIDATIVE STRESS; THERAPY;

ANGIOTENSIN II; ANIMALS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; DIET; GENETIC THERAPY; HUMANS; NANOPARTICLES; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM;

EID: 84878596688     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00395.2012     Document Type: Review

References (162)

1. Albuquerque MN, Diniz AS, Arruda IK. Retinolemia, vitamin A intake, and blood pressure in the elderly. Arch Latinoam Nutr 59: 396-401, 2009.
2. Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 81: 2605-2609, 2000.
3. Augusti PR, Conterato GM, Somacal S, Sobieski R, Quatrin A, Maurer L, Rocha MP, Denardin IT, Emanuelli T. Astaxanthin reduces oxidative stress, but not aortic damage in atherosclerotic rabbits. J Cardiovasc Pharmacol Ther 14: 314-322, 2009.
4. Bader M, Peters J, Baltatu O, Muller DN, Luft FC, Ganten D. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med 79: 76-102, 2001.
5. Ballinger SW. Mitochondrial dysfunction in cardiovascular disease. Free Radic Biol Med 38: 1278-1295, 2005.
6. Bansal P, Gupta SK, Ojha SK, Nandave M, Mittal R, Kumari S, Arya DS. Cardioprotective effect of lycopene in the experimental model of myocardial ischemia-reperfusion injury. Mol Cell Biochem 289: 1-9, 2006.
7. Batinic-Haberle I, Rajic Z, Tovmasyan A, Reboucas JS, Ye X, Leong KW, Dewhirst MW, Vujaskovic Z, Benov L, Spasojevic I. Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics. Free Radic Biol Med 51: 1035-1053, 2011.
8. Batrakova EV, Vinogradov SV, Robinson SM, Niehoff ML, Banks WA, Kabanov AV. Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery. Bioconjug Chem 16: 793-802, 2005.
9. Bayorh MA, Mann G, Walton M, Eatman D. Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in Dahl salt-sensitive rats. Clin Exp Hypertens 28: 121-132, 2006.
10. Beckman JS, Minor RL Jr,. White CW, Repine JE, Rosen GM, Freeman BA. Superoxide dismutase and catalase conjugated to polyethylene glycol increases endothelial enzyme activity and oxidant resistance. J Biol Chem 263: 6884-6892, 1988.
11. Bhatt SR, Lokhandwala MF, Banday AA. Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats. Eur J Pharmacol 667: 258-264, 2011.
12. Bose KS, Agrawal BK. Effect of lycopene from tomatoes (cooked) on plasma antioxidant enzymes, lipid peroxidation rate and lipid profile in grade-I hypertension. Ann Nutr Metab 51: 477-481, 2007.
13. Boshtam M, Rafiei M, Sadeghi K, Sarraf-Zadegan N. Vitamin E can reduce blood pressure in mild hypertensives. Int J Vitam Nutr Res 72: 309-314, 2002.
14. Brown AA, Hu FB. Dietary modulation of endothelial function: implications for cardiovascular disease. Am J Clin Nutr 73: 673-686, 2001.
15. Buttros JB, Bergamaschi CT, Ribeiro DA, Fracalossi AC, Campos RR. Cardioprotective actions of ascorbic acid during isoproterenolinduced acute myocardial infarction in rats. Pharmacology 84: 29-37, 2009.
16. Campese VM, Shaohua Y, Huiquin Z. Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension 46: 533-539, 2005.
17. Chan SH, Tai MH, Li CY, Chan JY. Reduction in molecular synthesis or enzyme activity of superoxide dismutases and catalase contributes to oxidative stress and neurogenic hypertension in spontaneously hypertensive rats. Free Radic Biol Med 40: 2028-2039, 2006.
18. Chan SH, Wu KL, Chang AY, Tai MH, Chan JY. Oxidative impairment of mitochondrial electron transport chain complexes in rostral ventrolateral medulla contributes to neurogenic hypertension. Hypertension 53: 217-227, 2009.
19. Chatterjee PK, Cuzzocrea S, Brown PA, Zacharowski K, Stewart KN, Mota-Filipe H, Thiemermann C. Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat. Kidney Int 58: 658-673, 2000.
20. Chen YR, Yi FF, Li XY, Wang CY, Chen L, Yang XC, Su PX, Cai J. Resveratrol attenuates ventricular arrhythmias and improves the longterm survival in rats with myocardial infarction. Cardiovasc Drugs Ther 22: 479-485, 2008.
21. Chung S, Park CW, Shin SJ, Lim JH, Chung HW, Youn DY, Kim HW, Kim BS, Lee JH, Kim GH, Chang YS. Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats. Nephrol Dial Transplant 25: 389-399, 2010.
22. Costa CA, Amaral TA, Carvalho LC, Ognibene DT, da Silva AF, Moss MB, Valenca SS, de Moura RS, Resende AC. Antioxidant treatment with tempol and apocynin prevents endothelial dysfunction and development of renovascular hypertension. Am J Hypertens 22: 1242-1249, 2009.
23. Costantini LC, Bakowska JC, Breakefield XO, Isacson O. Gene therapy in the CNS. Gene Ther 7: 93-109, 2000.
24. Csiszar A. Anti-inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease. Ann N Y Acad Sci 1215: 117-122, 2011.
25. Curek GD, Cort A, Yucel G, Demir N, Ozturk S, Elpek GO, Savas B, Aslan M. Effect of astaxanthin on hepatocellular injury following ischemia/reperfusion. Toxicology 267: 147-153, 2010.
26. Day BJ. Catalase and glutathione peroxidase mimics. Biochem Pharmacol 77: 285-296, 2009.
27. Descamps D, Benihoud K. Two key challenges for effective adenovirusmediated liver gene therapy: innate immune responses and hepatocytespecific transduction. Curr Gene Ther 9: 115-127, 2009.
28. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 28: 506-514, 1996.
29. DiBianco R. Update on therapy for heart failure. Am J Med 115: 480-488, 2003.
30. Ding Y, Li YL, Zimmerman MC, Davisson RL, Schultz HD. Role of CuZn superoxide dismutase on carotid body function in heart failure rabbits. Cardiovasc Res 81: 678-685, 2009.
31. Ding Y, Li YL, Zimmerman MC, Schultz HD. Elevated mitochondrial superoxide contributes to enhanced chemoreflex in heart failure rabbits. Am J Physiol Regul Integr Comp Physiol 298: R303-R311, 2010.
32. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 102: 488-496, 2008.
33. Duffy SJ, Gokce N, Holbrook M, Huang A, Frei B, Keaney JF Jr., Vita JA. Treatment of hypertension with ascorbic acid. Lancet 354: 2048-2049, 1999.
34. Duffy SJ, Gokce N, Holbrook M, Hunter LM, Biegelsen ES, Huang A, Keaney JF Jr., Vita JA. Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension. Am J Physiol Heart Circ Physiol 280: H528-H534, 2001.
35. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 35: 1270-1277, 2000.
36. Farmer JA, Torre-Amione G. The renin angiotensin system as a risk factor for coronary artery disease. Curr Atheroscler Rep 3: 117-124, 2001.
37. Fassett RG, Coombes JS. Astaxanthin, oxidative stress, inflammation and cardiovascular disease. Future Cardiol 5: 333-342, 2009.
38. Flores-Arredondo JH, Garcia-Rivas G, Torre-Amione G. Immune modulation in heart failure: past challenges and future hopes. Curr Heart Fail Rep 8: 28-37, 2011.
39. Fotherby MD, Williams JC, Forster LA, Craner P, Ferns GA. Effect of vitamin C on ambulatory blood pressure and plasma lipids in older persons. J Hypertens 18: 411-415, 2000.
40. Fretheim A, Odgaard-Jensen J, Brors O, Madsen S, Njolstad I, Norheim OF, Svilaas A, Kristiansen IS, Thurmer H, Flottorp S. Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis. BMC Med 10: 33, 2012.
41. Galleano M, Pechanova O, Fraga CG. Hypertension, nitric oxide, oxidants, and dietary plant polyphenols. Curr Pharm Biotechnol 11: 837-848, 2010.
42. Gao L, Wang W, Liu D, Zucker IH. Exercise training normalizes sympathetic outflow by central antioxidant mechanisms in rabbits with pacing-induced chronic heart failure. Circulation 115: 3095-3102, 2007.
43. Granger DN, Vowinkel T, Petnehazy T. Modulation of the inflammatory response in cardiovascular disease. Hypertension 43: 924-931, 2004.
44. Guo F, Chen XL, Wang F, Liang X, Sun YX, Wang YJ. Role of angiotensin II type 1 receptor in angiotensin II-induced cytokine production in macrophages. J Interferon Cytokine Res 31: 351-361, 2011.
45. Han J, Shuvaev VV, Muzykantov VR. Catalase and superoxide dismutase conjugated with platelet-endothelial cell adhesion molecule antibody distinctly alleviate abnormal endothelial permeability caused by exogenous reactive oxygen species and vascular endothelial growth factor. J Pharmacol Exp Ther 338: 82-91, 2011.
46. Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am 93: 621-635, 2009.
47. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM. Inflammation, immunity, and hypertension. Hypertension 57: 132-140, 2011.
48. Hekimoglu A, Kurcer Z, Aral F, Baba F, Sahna E, Atessahin A. Lycopene, an antioxidant carotenoid, attenuates testicular injury caused by ischemia/reperfusion in rats. Tohoku J Exp Med 218: 141-147, 2009.
49. Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol 148: 291-300, 1996.
50. Hosseini F, Naseri MK, Badavi M, Ghaffari MA, Shahbazian H, Rashidi I. Protective effect of beta carotene pretreatment on renal ischemia/reperfusion injury in rat. Pak J Biol Sci 12: 1140-1145, 2009.
51. Hosseini F, Naseri MK, Badavi M, Ghaffari MA, Shahbazian H, Rashidi I. Effect of beta carotene on lipid peroxidation and antioxidant status following renal ischemia/reperfusion injury in rat. Scand J Clin Lab Invest 70: 259-263, 2010.
52. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 117: 234-242, 1992.
53. Jablonski KL, Seals DR, Eskurza I, Monahan KD, Donato AJ. High-dose ascorbic acid infusion abolishes chronic vasoconstriction and restores resting leg blood flow in healthy older men. J Appl Physiol 103: 1715-1721, 2007.
54. Kabanov AV, Alakhov VY. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst 19: 1-72, 2002.
55. Kang YM, Ma Y, Elks C, Zheng JP, Yang ZM, Francis J. Cross-talk between cytokines and renin-angiotensin in hypothalamic paraventricular nucleus in heart failure: role of nuclear factor-κB. Cardiovasc Res 79: 671-678, 2008.
56. Kataja-Tuomola MK, Kontto JP, Mannisto S, Albanes D, Virtamo JR. Effect of alpha-tocopherol and beta-carotene supplementation on macrovascular complications and total mortality from diabetes: results of the ATBC Study. Ann Med 42: 178-186, 2010.
57. Kazama K, Anrather J, Zhou P, Girouard H, Frys K, Milner TA, Iadecola C. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res 95: 1019-1026, 2004.
58. Kim KS, Khang G, Lee D. Application of nanomedicine in cardiovascular diseases and stroke. Curr Pharm Des 17: 1825-1833, 2011.
59. Kim S, Park H, Song Y, Hong D, Kim O, Jo E, Khang G, Lee D. Reduction of oxidative stress by p-hydroxybenzyl alcohol-containing biodegradable polyoxalate nanoparticulate antioxidant. Biomaterials 32: 3021-3029, 2011.
60. Kitada M, Kume S, Imaizumi N, Koya D. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 60: 634-643, 2011.
61. Kleemann R, Verschuren L, Morrison M, Zadelaar S, van Erk MJ, Wielinga PY, Kooistra T. Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis 218: 44-52, 2011.
62. Klyachko NL, Manickam DS, Brynskikh AM, Uglanova SV, Li S, Higginbotham SM, Bronich TK, Batrakova EV, Kabanov AV. Crosslinked antioxidant nanozymes for improved delivery to CNS. Nanomedicine 8: 119-129, 2012.
63. Korkmaz A, Kolankaya D. The protective effects of ascorbic acid against renal ischemia-reperfusion injury in male rats. Ren Fail 31: 36-43, 2009.
64. Lagowska-Lenard M, Stelmasiak Z, Bartosik-Psujek H. Influence of vitamin C on markers of oxidative stress in the earliest period of ischemic stroke. Pharmacol Rep 62: 751-756, 2010.
65. Lavoie JL, Sigmund CD. Overview of the renin-angiotensin system: An endocrine and paracrine system. Endocrinology 144: 2179-2183, 2003.
66. Lee D, Erigala VR, Dasari M, Yu J, Dickson RM, Murthy N. Detection of hydrogen peroxide with chemiluminescent micelles. Int J Nanomedicine 3: 471-476, 2008.
67. Lee D, Khaja S, Velasquez-Castano JC, Dasari M, Sun C, Petros J, Taylor WR, Murthy N. In vivo imaging of hydrogen peroxide with chemiluminescent nanoparticles. Nat Mater 6: 765-769, 2007.
68. Lee MY, Griendling KK. Redox signaling, vascular function, and hypertension. Antioxid Redox Signal 10: 1045-1059, 2008.
69. Li Q, Bolli R, Qiu Y, Tang XL, Guo Y, French BA. Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction. Circulation 103: 1893-1898, 2001.
70. Li Q, Bolli R, Qiu Y, Tang XL, Murphree SS, French BA. Gene therapy with extracellular superoxide dismutase attenuates myocardial stunning in conscious rabbits. Circulation 98: 1438-1448, 1998.
71. Li XC, Zhuo JL. Nuclear factor-κB as a hormonal intracellular signaling molecule: focus on angiotensin II-induced cardiovascular and renal injury. Curr Opin Nephrol Hypertens 17: 37-43, 2008.
72. Li YL, Gao L, Zucker IH, Schultz HD. NADPH oxidase-derived superoxide anion mediates angiotensin II-enhanced carotid body chemoreceptor sensitivity in heart failure rabbits. Cardiovasc Res 75: 546-554, 2007.
73. Lindley TE, Doobay MF, Sharma RV, Davisson RL. Superoxide is involved in the central nervous system activation and sympathoexcitation of myocardial infarction-induced heart failure. Circ Res 94: 402-409, 2004.
74. Lindley TE, Infanger DW, Rishniw M, Zhou Y, Doobay MF, Sharma RV, Davisson RL. Scavenging superoxide selectively in mouse forebrain is associated with improved cardiac function and survival following myocardial infarction. Am J Physiol Regul Integr Comp Physiol 296: R1-R8, 2009.
75. Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, Mann JF, Gerstein HC. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25: 1919-1927, 2002.
76. Lu N, Helwig BG, Fels RJ, Parimi S, Kenney MJ. Central Tempol alters basal sympathetic nerve discharge and attenuates sympathetic excitation to central ANG II. Am J Physiol Heart Circ Physiol 287: H2626-H2633, 2004.
77. Mao Z, Liang Y, Du X, Sun Z. 3,3',4',5,7-Pentamethylquercetin reduces angiotensin II-induced cardiac hypertrophy and apoptosis in rats. Can J Physiol Pharmacol 87: 720-728, 2009.
78. Marvar PJ, Lob H, Vinh A, Zarreen F, Harrison DG. The central nervous system and inflammation in hypertension. Curr Opin Pharmacol 11: 156-161, 2011.
79. Marvar PJ, Thabet SR, Guzik TJ, Lob HE, McCann LA, Weyand C, Gordon FJ, Harrison DG. Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circ Res 107: 263-270, 2010.
80. Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 148: 16-29, 2008.
81. McKinney JS, Willoughby KA, Liang S, Ellis EF. Stretch-induced injury of cultured neuronal, glial, and endothelial cells. Effect of polyethylene glycol-conjugated superoxide dismutase. Stroke 27: 934-940, 1996.
82. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol 150: 552-558, 2007.
83. Meyers DG, Maloley PA. The antioxidant vitamins: impact on atherosclerosis. Pharmacotherapy 13: 574-582, 1993.
84. Mickle DA, Li RK, Weisel RD, Birnbaum PL, Wu TW, Jackowski G, Madonik MM, Burton GW, Ingold KU. Myocardial salvage with trolox and ascorbic acid for an acute evolving infarction. Ann Thorac Surg 47: 553-557, 1989.
85. Minicucci MF, Azevedo PS, Oliveira SA Jr, Martinez PF, Chiuso- Minicucci F, Polegato BF, Justulin LA Jr, Matsubara LS, Matsubara BB, Paiva SA, Zornoff LA. Tissue vitamin A insufficiency results in adverse ventricular remodeling after experimental myocardial infarction. Cell Physiol Biochem 26: 523-530, 2010.
86. Monroy-Ruiz J, Sevilla MA, Carron R, Montero MJ. Astaxanthinenriched- diet reduces blood pressure and improves cardiovascular parameters in spontaneously hypertensive rats. Pharmacol Res 63: 44-50, 2011.
87. Montezano AC, Touyz RM. Reactive oxygen species and endothelial function-role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases. Basic Clin Pharmacol Toxicol 110: 87-94, 2012.
88. Moreau KL, DePaulis AR, Gavin KM, Seals DR. Oxidative stress contributes to chronic leg vasoconstriction in estrogen-deficient postmenopausal women. J Appl Physiol 102: 890-895, 2007.
89. Morimoto S, Sigmund CD. Angiotensin mutant mice: a focus on the brain renin-angiotensin system. Neuropeptides 36: 194-200, 2002.
90. Mullan BA, Young IS, Fee H, McCance DR. Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes. Hypertension 40: 804-809, 2002.
91. Muro S, Dziubla T, Qiu W, Leferovich J, Cui X, Berk E, Muzykantov VR. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J Pharmacol Exp Ther 317: 1161-1169, 2006.
92. Muzykantov VR. Targeting of superoxide dismutase and catalase to vascular endothelium. J Control Release 71: 1-21, 2001.
93. Neyestani TR, Shariatzadeh N, Gharavi A, Kalayi A, Khalaji N. Physiological dose of lycopene suppressed oxidative stress and enhanced serum levels of immunoglobulin M in patients with Type 2 diabetes mellitus: a possible role in the prevention of long-term complications. J Endocrinol Invest 30: 833-838, 2007.
94. Nguyen Dinh CA, Montezano AC, Burger D, Touyz RM. Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxid Redox Signal In press.
95. Nielsen AH, Schauser KH, Poulsen K. Current topic: the uteroplacental renin-angiotensin system. Placenta 21: 468-477, 2000.
96. Nilakantan V, Liang HL, Rajesh S, Mortensen J, Chandran K. Time-dependant protective effects of mangenese(III) tetrakis (1-methyl- 4-pyridyl) porphyrin on mitochondrial function following renal ischemia- reperfusion injury. Free Radic Res 44: 773-782, 2010.
97. Niu J, Azfer A, Rogers LM, Wang X, Kolattukudy PE. Cardioprotective effects of cerium oxide nanoparticles in a transgenic murine model of cardiomyopathy. Cardiovasc Res 73: 549-559, 2007.
98. Odlind B, Appelgren LE, Bayati A, Wolgast M. Tissue distribution of 125I-labelled bovine superoxide dismutase (SOD) in the rat. Pharmacol Toxicol 62: 95-100, 1988.
99. Offer T, Russo A, Samuni A. The pro-oxidative activity of SOD and nitroxide SOD mimics. FASEB J 14: 1215-1223, 2000.
100. Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms, and management. Drug Saf 15: 72-78, 1996.
101. Paiva SA, Russell RM. Beta-carotene and other carotenoids as antioxidants. J Am Coll Nutr 18: 426-433, 1999.
102. Palace VP, Hill MF, Farahmand F, Singal PK. Mobilization of antioxidant vitamin pools and hemodynamic function after myocardial infarction. Circulation 99: 121-126, 1999.
103. Palm F, Onozato M, Welch WJ, Wilcox CS. Blood pressure, blood flow, and oxygenation in the clipped kidney of chronic 2-kidney, 1-clip rats: effects of tempol and angiotensin blockade. Hypertension 55: 298-304, 2010.
104. Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, Gheorghiade M, Ahmed A. Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. Eur J Heart Fail 14: 1179-1188, 2012.
105. Petkau A, Chelack WS, Kelly K, Barefoot C, Monasterski L. Tissue distribution of bovine 125I-superoxide dismutase in mice. Res Commun Chem Pathol Pharmacol 15: 641-654, 1976.
106. Petrat F, de Groot H. Protection against severe intestinal ischemia/ reperfusion injury in rats by intravenous resveratrol. J Surg Res 167: e145-e155, 2011.
107. Prasad K, Gupta JB, Kalra J, Bharadwaj B. Oxygen free radicals in volume overload heart failure. Mol Cell Biochem 111: 55-59, 1992.
108. Price TO, Farr SA, Yi X, Vinogradov S, Batrakova E, Banks WA, Kabanov AV. Transport across the blood-brain barrier of pluronic leptin. J Pharmacol Exp Ther 333: 253-263, 2010.
109. Punithavathi VR, Stanely Mainzen Prince P. The cardioprotective effects of a combination of quercetin and alpha-tocopherol on isoproterenol- induced myocardial infarcted rats. J Biochem Mol Toxicol 25: 28-40, 2011.
110. Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther 30: e156-e166, 2012.
111. Raizada V, Skipper B, Luo W, Griffith J. Intracardiac and intrarenal renin-angiotensin systems: mechanisms of cardiovascular and renal effects. J Investig Med 55: 341-359, 2007.
112. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/ NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97: 1916-1923, 1996.
113. Rao AV, Rao LG. Carotenoids and human health. Pharmacol Res 55: 207-216, 2007.
114. Reddy MK, Labhasetwar V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemiareperfusion injury. FASEB J 23: 1384-1395, 2009.
115. Riccioni G, Bucciarelli T, D'Orazio N, Palumbo N, Di IE, Corradi F, Pennelli A, Bazzano LA. Plasma antioxidants and asymptomatic carotid atherosclerotic disease. Ann Nutr Metab 53: 86-90, 2008.
116. Riccioni G, D'Orazio N, Speranza L, Di IE, Glade M, Bucciarelli V, Scotti L, Martini F, Pennelli A, Bucciarelli T. Carotenoids and asymptomatic carotid atherosclerosis. J Biol Regul Homeost Agents 24: 447-452, 2010.
117. Ried K, Fakler P. Protective effect of lycopene on serum cholesterol and blood pressure: Meta-analyses of intervention trials. Maturitas 68: 299-310, 2011.
118. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 328: 1450-1456, 1993.
119. Rosenbaugh EG, Roat JW, Gao L, Yang RF, Manickam DS, Yin JX, Schultz HD, Bronich TK, Batrakova EV, Kabanov AV, Zucker IH, Zimmerman MC. The attenuation of central angiotensin II-dependent pressor response and intra-neuronal signaling by intracarotid injection of nanoformulated copper/zinc superoxide dismutase. Biomaterials 31: 5218-5226, 2010.
120. Sakata Y, Zhuang H, Kwansa H, Koehler RC, Dore S. Resveratrol protects against experimental stroke: putative neuroprotective role of heme oxygenase 1. Exp Neurol 224: 325-329, 2010.
121. Savoia C, Burger D, Nishigaki N, Montezano A, Touyz RM. Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med 13: e11, 2011.
122. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens 15: 152-158, 2006.
123. Schiffrin EL. Antioxidants in hypertension and cardiovascular disease. Mol Interv 10: 354-362, 2010.
124. Sernia C. A critical appraisal of the intrinsic pancreatic angiotensingenerating system. JOP 2: 50-55, 2001.
125. Seshadri G, Sy JC, Brown M, Dikalov S, Yang SC, Murthy N, Davis ME. The delivery of superoxide dismutase encapsulated in polyketal microparticles to rat myocardium and protection from myocardial ischemia- reperfusion injury. Biomaterials 31: 1372-1379, 2010.
126. Shastri S, Gopalakrishnan V, Poduri R, Di WH. Tempol selectively attenuates angiotensin II evoked vasoconstrictor responses in spontaneously hypertensive rats. J Hypertens 20: 1381-1391, 2002.
127. Shi Z, Chen AD, Xu Y, Chen Q, Gao XY, Wang W, Zhu GQ. Long-term administration of tempol attenuates postinfarct ventricular dysfunction and sympathetic activity in rats. Pflügers Arch 458: 247-257, 2009.
128. Shuvaev VV, Han J, Yu KJ, Huang S, Hawkins BJ, Madesh M, Nakada M, Muzykantov VR. PECAM-targeted delivery of SOD inhibits endothelial inflammatory response. FASEB J 25: 348-357, 2011.
129. Shuvaev VV, Tliba S, Nakada M, Albelda SM, Muzykantov VR. Platelet-endothelial cell adhesion molecule-1-directed endothelial targeting of superoxide dismutase alleviates oxidative stress caused by either extracellular or intracellular superoxide. J Pharmacol Exp Ther 323: 450-457, 2007.
130. Siow RC, Sato H, Leake DS, Ishii T, Bannai S, Mann GE. Induction of antioxidant stress proteins in vascular endothelial and smooth muscle cells: protective action of vitamin C against atherogenic lipoproteins. Free Radic Res 31: 309-318, 1999.
131. Sirker A, Zhang M, Shah AM. NADPH oxidases in cardiovascular disease: insights from in vivo models and clinical studies. Basic Res Cardiol 106: 735-747, 2011.
132. Speth RC, Daubert DL, Grove KL. Angiotensin II: a reproductive hormone too? Regul Pept 79: 25-40, 1999.
133. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 328: 1444-1449, 1993.
134. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347: 781-786, 1996.
135. 2+ currents: intracellular mechanisms. Am J Physiol Cell Physiol 271: C154-C163, 1996.
136. Sun C, Sumners C, Raizdaa MK. Chronotropic action of angiotensin II in neurons via protein kinase C and CaMKII. Hypertension 39: 562-566, 2002.
137. Sun C, Du J, Raizada MK, Sumners C. Modulation of delayed rectifier potassium current by angiotensin II in CATH.a cells. Biochem Biophys Res Commun 310: 710-714, 2003.
138. Sweitzer TD, Thomas AP, Wiewrodt R, Nakada MT, Branco F, Muzykantov VR. PECAM-directed immunotargeting of catalase: specific, rapid and transient protection against hydrogen peroxide. Free Radic Biol Med 34: 1035-1046, 2003.
139. Sy JC, Davis ME. Delivering regenerative cues to the heart: cardiac drug delivery by microspheres and peptide nanofibers. J Cardiovasc Transl Res 3: 461-468, 2010.
140. Touyz RM. Oxidative stress and vascular damage in hypertension. Curr Hypertens Rep 2: 98-105, 2000.
141. Touyz RM. Reactive oxygen species and angiotensin II signaling in vascular cells-implications in cardiovascular disease. Braz J Med Biol Res 37: 1263-1273, 2004.
142. Touyz RM, Tabet F, Schiffrin EL. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol 30: 860-866, 2003.
143. Veronese FM, Caliceti P, Schiavon O, Sergi M. Polyethylene glycolsuperoxide dismutase, a conjugate in search of exploitation. Adv Drug Deliv Rev 54: 587-606, 2002.
144. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: metaanalysis of randomised trials. Lancet 361: 2017-2023, 2003.
145. Wang D, Luo Z, Wang X, Jose PA, Falck JR, Welch WJ, Aslam S, Teerlink T, Wilcox CS. Impaired endothelial function and microvascular asymmetrical dimethylarginine in angiotensin II-infused rats: effects of tempol. Hypertension 56: 950-955, 2010.
146. Wang H, Yang YJ, Qian HY, Zhang Q, Xu H, Li JJ. Resveratrol in cardiovascular disease: what is known from current research? Heart Fail Rev 17: 437-448, 2012.
147. Widlansky ME, Biegelsen ES, Hamburg NM, Duffy SJ, Keaney JF Jr, Vita JA. Coronary endothelial dysfunction is not rapidly reversible with ascorbic acid. Free Radic Biol Med 36: 123-130, 2004.
148. Wongmekiat O, Thamprasert K, Lumlertgul D. Renoprotective effect of trolox against ischaemia-reperfusion injury in rats. Clin Exp Pharmacol Physiol 34: 753-759, 2007.
149. Woo YJ, Zhang JC, Vijayasarathy C, Zwacka RM, Englehardt JF, Gardner TJ, Sweeney HL. Recombinant adenovirus-mediated cardiac gene transfer of superoxide dismutase and catalase attenuates postischemic contractile dysfunction. Circulation 98: II255-II260, 1998.
150. Wu JM, Hsieh TC. Resveratrol: a cardioprotective substance. Ann N Y Acad Sci 1215: 16-21, 2011.
151. Yamagishi S, Maeda S, Matsui T, Ueda S, Fukami K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim Biophys Acta 1820: 663-671, 2012.
152. Yi X, Batrakova E, Banks WA, Vinogradov S, Kabanov AV. Protein conjugation with amphiphilic block copolymers for enhanced cellular delivery. Bioconjug Chem 19: 1071-1077, 2008.
153. Yi X, Zimmerman MC, Yang R, Tong J, Vinogradov S, Kabanov AV. Pluronic-modified superoxide dismutase 1 attenuates angiotensin II-induced increase in intracellular superoxide in neurons. Free Radic Biol Med 49: 548-558, 2010.
154. Yin JX, Yang RF, Li S, Renshaw AO, Li YL, Schultz HD, Zimmerman MC. Mitochondria-produced superoxide mediates angiotensin IIinduced inhibition of neuronal potassium current. Am J Physiol Cell Physiol 298: C857-C865, 2010.
155. Yin M, Wheeler MD, Connor HD, Zhong Z, Bunzendahl H, Dikalova A, Samulski RJ, Schoonhoven R, Mason RP, Swenberg JA, Thurman RG. Cu/Zn-superoxide dismutase gene attenuates ischemia-reperfusion injury in the rat kidney. J Am Soc Nephrol 12: 2691-2700, 2001.
156. Yoshida K, Burton GF, McKinney JS, Young H, Ellis EF. Brain and tissue distribution of polyethylene glycol-conjugated superoxide dismutase in rats. Stroke 23: 865-869, 1992.
157. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 154-160, 2000.
158. Zablocki D, Sadoshima J. Angiotensin II and oxidative stress in the failing heart. Antioxid Redox Signal In press.
159. Zhong MK, Gao J, Zhang F, Xu B, Fan ZD, Wang W, Zhu GQ. Reactive oxygen species in rostral ventrolateral medulla modulate cardiac sympathetic afferent reflex in rats. Acta Physiol (Oxf) 197: 297-304, 2009.
160. Zimmerman MC, Lazartigues E, Lang JA, Sinnayah P, Ahmad IM, Spitz DR, Davisson RL. Superoxide mediates the actions of angiotensin II in the central nervous system. Circ Res 91: 1038-1045, 2002.
161. Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res 95: 210-216, 2004.
162. Zimmerman MC, Sharma RV, Davisson RL. Superoxide mediates angiotensin II-induced influx of extracellular calcium in neural cells. Hypertension 45: 717-723, 2005.